Despite dramatic expansion over the past 34 years, many rural and underserved hospitals continue to face significant ...

Ravin Consultants announced today a leadership evolution that reflects the strength of its foundation and its long-term vision for the future of the 340B program. This press release features ...

The steady global growth of the healthcare 3PL market is primarily attributed to the growing pharmaceutical industry, rising demand for biologics with increasing cold chain logistics needs followed by ...

The 340B drug plan language that was recently added into Senate Bill 494 risks increasing costs for the very patients it ...

AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount program with a lawsuit that challenges the definition of what it means to be a ...

HRSA has extended the deadline for comments on its proposed 340B rebate model pilot program to April 20, 2026. Covered entities have a limited window to submit detailed feedback on how the model would ...

Tax-exempt hospitals in Minnesota that have raked in large sums of revenue from a government safety net program spent tens of ...

In February 2026, the Department of Justice filed amicus briefs supporting pharmaceutical manufacturers, asserting that Rhode Island and Colorado’s 340B laws conflict with the federal 340B Program and ...

The AHA responds to the Health Resources and Services Administration’s (HRSA) Request for Information regarding a potential 340B Rebate Model Pilot Program.

The American Hospital Association (AHA) writes to alert you to the latest development in connection with the growing number ...

The American Hospital Association has called on federal regulators to intervene after Eli Lilly sent warning letters to 340B hospitals threatening to cut off discounted drug pricing unless they submit ...